City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  85  Clinical trial(s) found  (Page 1 of 4 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 16215 ClinicalTrials.gov Number: NCT02030067

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies

COH Protocol Number: 16195 ClinicalTrials.gov Number: NCT02496663

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-77, NCI#9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

COH Protocol Number: 16176 ClinicalTrials.gov Number: NCT02448251

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II, Multicenter, Open-label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 16125 ClinicalTrials.gov Number: NCT02743351

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1 Non-Randomized/Phase 2 Randomized Study of ProTmune™ (ex vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Hematologic Malignancies

COH Protocol Number: 16107 ClinicalTrials.gov Number: NCT01307267

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1 Study of PF-05082566 as a Single Agent in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin’s Lymphoma (NHL)

COH Protocol Number: 16102 ClinicalTrials.gov Number: NCT02283775

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1b Study of SAR650984 (Isatuximab) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 16059 ClinicalTrials.gov Number: NCT02684617

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)

COH Protocol Number: 16049 ClinicalTrials.gov Number: NCT02759016

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Phase Ib/II, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

COH Protocol Number: 16006 ClinicalTrials.gov Number: NCT02453087

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I/IB Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination with Rituximab, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

COH Protocol Number: 15467 ClinicalTrials.gov Number: NCT01953692

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies

COH Protocol Number: 15429 ClinicalTrials.gov Number: NCT02677922

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects with Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

COH Protocol Number: 15428 ClinicalTrials.gov Number: NCT02567656

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

COH Protocol Number: 15404 ClinicalTrials.gov Number: NCT02419560

Principal Investigator: Robert Chen, MD
Sponsor: Institutional

Title:  Multi-institution Phase I/Ib Study of Ibrutinib with ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma

COH Protocol Number: 15391 ClinicalTrials.gov Number: NCT02500407

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

COH Protocol Number: 15385 ClinicalTrials.gov Number: NCT02603419

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1 Pharmacokinetic-Pharmacodynamic Study Of Avelumab (MSB0010718C) In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma

COH Protocol Number: 15358 ClinicalTrials.gov Number: NCT02625480

Principal Investigator: Joseph Rosenthal, MD
Sponsor: Industrial

Title:  A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

COH Protocol Number: 15340 ClinicalTrials.gov Number: NCT02548962

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Randomized Multicenter Study of Ibrutinib in Combination with Pomalidomide (Pomalyst™) and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 15337 ClinicalTrials.gov Number: NCT02610062

Principal Investigator: Monzr Al malki, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating Safety,Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

COH Protocol Number: 15335 ClinicalTrials.gov Number: NCT02614560

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence with Allogeneic Hematopoietic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

COH Protocol Number: 15333 ClinicalTrials.gov Number: NCT02632708

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

COH Protocol Number: 15321 ClinicalTrials.gov Number: NCT02663518

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1a/1b Dose Escalation and Expansion Trial of Single-agent TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies

COH Protocol Number: 15318 ClinicalTrials.gov Number: NCT02702141

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19B in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

COH Protocol Number: 15303 ClinicalTrials.gov Number: NCT02592577

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15275 ClinicalTrials.gov Number: NCT02588612

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15270 ClinicalTrials.gov Number: NCT02580552

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.